Earnings Summary

Integra Lifesciences Holdings Corp’s revenue fell -3.14% since last year same period to $368.87Mn in the Q1 2024. On a quarterly growth basis, Integra Lifesciences Holdings Corp has generated -7.09% fall in its revenue since last 3-months.

Integra Lifesciences Holdings Corp’s net profit fell -113.54% since last year same period to $-3.28Mn in the Q1 2024. On a quarterly growth basis, Integra Lifesciences Holdings Corp has generated -116.54% fall in its net profits since last 3-months.

Integra Lifesciences Holdings Corp’s net profit margin fell -113.98% since last year same period to -0.89% in the Q1 2024. On a quarterly growth basis, Integra Lifesciences Holdings Corp has generated -117.81% fall in its net profit margins since last 3-months.

Integra Lifesciences Holdings Corp’s price-to-earnings ratio after this Q1 2024 earnings stands at 61.61.

Integra Lifesciences Holdings Corp’s earning per share (EPS) estimates for the current quarter stand at 0.62 - a 12.73% jump from last quarter’s estimates.

Integra Lifesciences Holdings Corp’s earning per share (EPS) estimates for the current year stand at 0.62.

Integra Lifesciences Holdings Corp’s earning per share (EPS) fell -25.68% since last year same period to 0.55 in the Q1 2024. This indicates that the Integra Lifesciences Holdings Corp has generated -25.68% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Integra Lifesciences Holdings Corp’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Integra Lifesciences Holdings Corp’s return on equity (ROE) stands at 0.02.